Shenzhen Salubris Pharmaceuticals Co Ltd (002294) - Total Liabilities
Based on the latest financial reports, Shenzhen Salubris Pharmaceuticals Co Ltd (002294) has total liabilities worth CN¥2.05 Billion CNY (≈ $300.34 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Shenzhen Salubris Pharmaceuticals Co Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
Shenzhen Salubris Pharmaceuticals Co Ltd - Total Liabilities Trend (2006–2024)
This chart illustrates how Shenzhen Salubris Pharmaceuticals Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Shenzhen Salubris Pharmaceuticals Co Ltd's balance sheet.
Shenzhen Salubris Pharmaceuticals Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shenzhen Salubris Pharmaceuticals Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shandong Intco Medical Products Co Ltd
SHE:300677
|
China | CN¥21.73 Billion |
|
Scout24 AG
XETRA:G24
|
Germany | €737.38 Million |
|
BRD Groupe Societe Generale SA
RO:BRD
|
Romania | RON89.65 Billion |
|
Mega Or
TA:MGOR
|
Israel | ILA6.54 Billion |
|
FOSITEK CORP
TW:6805
|
Taiwan | NT$8.79 Billion |
|
Laureate Education Inc
NASDAQ:LAUR
|
USA | $1.28 Billion |
|
Iridium Communications Inc
NASDAQ:IRDM
|
USA | $2.09 Billion |
|
Vipshop Holdings Limited
NYSE:VIPS
|
USA | $35.12 Billion |
Liability Composition Analysis (2006–2024)
This chart breaks down Shenzhen Salubris Pharmaceuticals Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Shenzhen Salubris Pharmaceuticals Co Ltd to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shenzhen Salubris Pharmaceuticals Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shenzhen Salubris Pharmaceuticals Co Ltd (2006–2024)
The table below shows the annual total liabilities of Shenzhen Salubris Pharmaceuticals Co Ltd from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.71 Billion ≈ $250.71 Million |
+27.74% |
| 2023-12-31 | CN¥1.34 Billion ≈ $196.27 Million |
-24.59% |
| 2022-12-31 | CN¥1.78 Billion ≈ $260.26 Million |
+48.43% |
| 2021-12-31 | CN¥1.20 Billion ≈ $175.34 Million |
-9.69% |
| 2020-12-31 | CN¥1.33 Billion ≈ $194.16 Million |
+24.36% |
| 2019-12-31 | CN¥1.07 Billion ≈ $156.12 Million |
+3.22% |
| 2018-12-31 | CN¥1.03 Billion ≈ $151.25 Million |
+46.43% |
| 2017-12-31 | CN¥705.86 Million ≈ $103.29 Million |
-34.28% |
| 2016-12-31 | CN¥1.07 Billion ≈ $157.17 Million |
+55.38% |
| 2015-12-31 | CN¥691.25 Million ≈ $101.15 Million |
-16.51% |
| 2014-12-31 | CN¥827.95 Million ≈ $121.16 Million |
+62.87% |
| 2013-12-31 | CN¥508.36 Million ≈ $74.39 Million |
+35.92% |
| 2012-12-31 | CN¥374.02 Million ≈ $54.73 Million |
+20.45% |
| 2011-12-31 | CN¥310.52 Million ≈ $45.44 Million |
+0.33% |
| 2010-12-31 | CN¥309.50 Million ≈ $45.29 Million |
+108.30% |
| 2009-12-31 | CN¥148.59 Million ≈ $21.74 Million |
+1.98% |
| 2008-12-31 | CN¥145.70 Million ≈ $21.32 Million |
+32.48% |
| 2007-12-31 | CN¥109.98 Million ≈ $16.09 Million |
+110.74% |
| 2006-12-31 | CN¥52.19 Million ≈ $7.64 Million |
-- |
About Shenzhen Salubris Pharmaceuticals Co Ltd
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also develops Sacubit… Read more